Pharsight

Austedo Xr is owned by Teva.

Austedo Xr contains Deutetrabenazine.

Austedo Xr has a total of 8 drug patents out of which 0 drug patents have expired.

Austedo Xr was authorised for market use on 17 February, 2023.

Austedo Xr is available in tablet, extended release;oral dosage forms.

Austedo Xr can be used as treatment of tardive dyskinesia, treatment of tardive dyskinesia; a method of treating huntington's chorea, a method of treating huntington's chorea.

The generics of Austedo Xr are possible to be released after 10 June, 2041.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8524733	September, 2021	Terminated-Denied	Auspex Pharmaceuticals, Inc.	Apotex Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8524733	TEVA	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr, 2031 (7 years from now)
US9550780	TEVA	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep, 2033 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11564917	TEVA	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (12 years from now)
US10959996	TEVA	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (12 years from now)
US11446291	TEVA	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (12 years from now)
US11357772	TEVA	Methods for the treatment of abnormal involuntary movement disorders	Mar, 2036 (12 years from now)
US11179386	TEVA	Analogs of deutetrabenazine, their preparation and use	Mar, 2038 (14 years from now)
US11311488	TEVA	Osmotic dosage forms comprising deutetrabenazine and methods of use thereof	Jun, 2041 (18 years from now)